Mustafa Khasraw, MD
Medical Oncology · New York, NYNPI 1235361353
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,855 of the $11,166 with a category attached, or 97.2%. 4 manufacturers reported payments, led by Janssen Global Services, LLC at 44.4% of the total. Reporting peaked in 2022 at $4,160 and has fallen 97.4% since, to $108 in 2024.
Across 8 payments — averaging $1395.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Global Services, LLC$5K
- Novocure Inc.$4K
- Daiichi Sankyo Inc.$2K
- GSK$108
Across 131 payments — averaging $2086.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$171K
- Biontech SE$102K
- Daiichi Sankyo Inc.$520
- Servier Pharmaceuticals LLC$84
What the payments were for
- Consulting fees$10,85597%
- Food & beverage$3113%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Global Services, LLC | 3 | $4,960 |
| Novocure Inc. | 2 | $4,160 |
| Daiichi Sankyo Inc. | 2 | $1,938 |
| GSK | 1 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$4,160
How this compares
$11,166 in reported general payments places this provider in the 60th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.